

R&D AUSTRIA

R&D GLOBAI



At Takeda, we exist to create better health for people and a brighter future for the world. Our global team of researchers and scientists harness cutting-edge science to push the boundaries of what is possible. We focus our R&D efforts on four therapeutic areas: Oncology, Gastroenterology, Neuroscience and Rare Diseases, and make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

R&D EMPLOYEES GLOBALLY

~5,000+



200+

Active collaborations APPROX.

New Molecular Entity Clinical Stage Assets

R&D AUSTRIA



R&D Austria is a central player in Takeda's global R&D engine. Our R&D activities in Austria cover the entire pharmaceutical development process from the selection of a product candidate over the monitoring of clinical trials up to the market release of the product.



We are focused on addressing high unmet medical need across our core therapeutic areas



We are acknowledged experts in recombinant biologics, and process development 5.0 platforms



We enable product candidates, develop & improve manufacturing processes to support clinical trials and market approval



We provide solutions to process and product related challenges in a fast-paced, highly professional environment



We developed 10+ medicines*



Medicines we develop are exported to 100+ countries worldwide



We are 200+ employees



We do cutting-edge research, publish in renown journals and successfully file for patents



WE SEEK INNOVATION AND PARTNER TO NURTURE IT, WHEREVER IT RESIDES

We work with partners to create complementary collaborations where our global reach, scientific expertise and clinical excellence can help them bring their scientific innovation and vision to patients. Our partners include academia, start-ups, research institutes, health care providers, student & alumni networks.

We want to be THE recognized and well-known partner of choice when working with academia/ start-ups in the field of product development and technology innovation in Europe."

Dr. Manfred RiegerSite Head R&D Austria



INDUSTRY 5.0 PLATFORMS

RECOMBINANT BIOLOGICS

Large complex recombinant proteins

Development of production processes for biologics Development of analytical methods and testing strategies Lab of the Future: Robotics, XR, Artificial intelligence,

in-silico CMC

Commercial production implementation and process validation

OUR

Analytics & Device Technologies Development platform & delivery systems

Automation & Robotics

Scientific & Know-how Exchange with experts

OUR NEW R&D AUSTRIA FACILITY

A new, state-of-the-art lab and office building in Vienna will become the main office of R&D Austria (planned opening date is 2026). This 'Lab of the Future' will be environmentally friendly, accessible, and modular, meeting the needs of a modern R&D organization. It will be equipped with high-end infrastructure to develop innovative technologies using robotics, augmented reality, artificial intelligence, and simulations of processes using digital twins.





+250 EMPLOYEES



~25.000 m²



GREEN BUILDING

RnD.Austria@takeda.com